Medical Devices

The advanced optics maker announced a stock offering to fund operations as it navigates record revenue growth alongside plummeting profitability.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

An Austin-based firm's rapid expansion to 150 partners shows how CE/CME is moving from conference halls to podcasts, apps, and on-demand platforms.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

With a 100% residency match, BayCare is doubling its medical training program, creating a vital pipeline of physicians to serve a rapidly growing Florida.

Renowned cardiac surgeon Dr. Robert C. Robbins brings his immense credibility to Linear Health Sciences, aiming to revolutionize patient care with a novel device.

A new wave of dentistry is here. MINISH Veneers is training U.S. dentists in a minimally invasive technique that preserves teeth and changes smiles.

As Milestone Scientific prepares its year-end call, investors look for signs of a turnaround and growth for its advanced injection technology.

Interlink Electronics reports a wider Q4 loss but makes key moves in autonomous vehicle and robotic surgery sensors, signaling a major strategic pivot.

The nation's top aesthetic clinic partners with BENEV to exclusively debut XTherma®, the first RF and cryogen device for pain-free skin rejuvenation.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

Shimadzu renews critical seismic certification for its X-ray systems, blending disaster resilience with smart imaging tech for California's hospitals.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Lumexa Imaging posted strong 2025 revenue and cut its debt, yet a surprise net loss and EPS miss sent its stock tumbling. What's next for the imaging giant?

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

Armata Pharmaceuticals posts a staggering $174M annual loss, triggering a 'going concern' alert, yet its promising phage therapy pipeline advances.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.